GLS and head and neck squamous cell carcinoma: Second and more importantly, Lang, et al. [45] show that targeting GLN metabolism with the CB839 glutaminase inhibitor under nutrient depleted in vivo conditions strongly sensitizes head and neck squamous cell carcinoma (HNSCC) xenografts to CPI-613.